Publications by authors named "Keke Lian"

Thermosensitive nanoparticles can be activated by externally applying heat, either through laser irradiation or magnetic fields, to trigger the release of drug payloads. This controlled release mechanism ensures that drugs are specifically released at the tumor site, maximizing their effectiveness while minimizing systemic toxicity and adverse effects. However, its efficacy is limited by the low concentration of drugs at action sites, which is caused by no specific target to tumor sties.

View Article and Find Full Text PDF
Article Synopsis
  • - Tumor-associated macrophages (TAMs) significantly contribute to tumor development through cytokine secretion and direct interaction with tumor cells, making them a promising target for therapy.
  • - Researchers created a specialized nanocarrier (Ex 26-CSOPOSA) that releases the c-Myc inhibitor JQ1 in response to reactive oxygen species (ROS) and targets both tumor cells and TAMs to induce cell death and prevent macrophage polarization.
  • - The study found that JQ1 not only inhibits tumor cell migration stimulated by M2 macrophages but also demonstrates a dual-targeting delivery method that effectively reduces tumor growth and metastasis while minimizing side effects.
View Article and Find Full Text PDF

Lymph nodes are proposed as the intriguing target in cancer immunotherapy, and cellular immunity is vital for vaccines to fight against cancer. However, inefficient delivery of vaccines to lymph nodes and deficient lysosomal escape of antigens result in weak cellular immunity, which restrains the strength of vaccines in inducing antitumor immune responses. Hence, dendritic cell membrane (DCM)/histidine-modified stearic acid-grafted chitosan (HCtSA)/ovalbumin (OVA) micelles, as pH-responsive biomimetic vaccines, were fabricated to target lymph nodes and induce cellular immunity for enhanced antitumor immune responses.

View Article and Find Full Text PDF

Tumor-draining lymph node (TDLN), already bathed in tumor antigens, has been proposed as an intriguing site for cancer immunotherapy. Targeted delivery of adjuvants to TDLN, presumably could induce antitumor immunity for personalized immunotherapy. Although molecular adjuvants can be used for personalized immunotherapy, their efficacy is limited by insufficient antigen uptake by dendritic cells (DCs).

View Article and Find Full Text PDF

Micelles are one of the most investigated nanocarriers for drug delivery. In this study, polymeric micelles based on chitosan were prepared to explore the delivery mechanism which was critical for enhancing tumor targeting but still remain elusive. The chitosan polymer COSA was synthesized and the polymeric micelles showed good self-assembly ability, good dispersion stability and low toxicity.

View Article and Find Full Text PDF

Cellular immunity is essential for the effectiveness of vaccines against cancer. After capture of vaccines, dendritic cells (DCs) have to migrate to lymph nodes via chemokine receptor type 7 (CCR7). Subsequently, DCs present cytosolic antigens via major histocompatibility complex class I (MHC I) molecules to induce cellular immunity.

View Article and Find Full Text PDF